Clinical trial
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent…
NCT00060645 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00060645 |
|---|---|
| Title | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) |
| Official title | A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Lymphoma, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 33 |
| Start date | May 1, 2003 |
| Primary completion | May 1, 2006 |
| Completion | Feb 1, 2009 |
| First posted | May 12, 2003 |
| Last update posted | Aug 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: